Research programme: therapeutic antibodies - Dyax/Glenmark
Latest Information Update: 10 Jun 2014
At a glance
- Originator Dyax; Glenmark Pharmaceuticals S.A.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Mar 2007 Early research in an undisclosed indication in the USA (unspecified route)